Cost-effectiveness analysis of different chemotherapeutical regimens in metastatic colorectal cancer.
- Author:
Tian-Shu LIU
1
;
Yi-Yi YU
;
Ying-Yao CHEN
Author Information
- Publication Type:Journal Article
- MeSH: Antineoplastic Combined Chemotherapy Protocols; economics; therapeutic use; Chemotherapy, Adjuvant; economics; Colorectal Neoplasms; drug therapy; economics; pathology; Cost-Benefit Analysis; economics; Humans
- From: Chinese Journal of Gastrointestinal Surgery 2008;11(2):120-123
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo compare FOLFOX6 and FOLFIRI regimen in the treatment of metastatic colorectal cancer with cost-effective analysis.
METHODSCost-effective analysis was conducted based on the efficacy results of V308 clinical trial of FOLFOX6 and FOLFIRI regimen and the medical system price in Zhongshan hospital.
RESULTSThe minimal cost analysis showed FOLFIRI followed by FOLFOX6 had the cost of RMB 206365.78 Yuan for each patient during the whole treatment period, and RMB 170468.89 Yuan for the FOLFOX6 followed by FOLFIRI regimen. Incremental analysis showed FOLFIRI followed by FOLFOX6 regimen could prolong one month of overall survival with additional cost of RMB 39885.44 Yuan in each patient while compared with the regimen of FOLFOX6 followed by FOLFIRI.
CONCLUSIONSBoth FOLFOX and FOLFIRI regimens are able to prolong the survival time of patients with metastatic colorectal cancer, but cost of such treatments are still quite expensive for Chinese patients. FOLFOX6 regimen suggests better cost-effectiveness than FOLFIRI.
